Sky rocketing obesity rates in certain segments of the population are heightening the demand for efficient percutaneous coronary intervention (PCI). High patient volumes have increased the clinical preference for simple outpatient PCI procedures over more complicated open heart procedures. The premier product in PCI therapy is the drug eluting stent.
New analysis from Frost & Sullivan (medicaldevices.frost.com), U.S. Coronary Stent Market, reveals that the market earned revenues of $3.27 billion in 2006 and estimates this to reach $4 billion in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Coronary Stent Market, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.
“Although only introduced in 2003, drug eluting stents reshaped the entire cardiovascular industry in a few short years. It made bypass procedures and their technologies nearly outmoded,” says Frost & Sullivan Research Analyst Venkat Rajan. “By 2005 nearly 90 percent of all stents being implanted were drug eluting devices over bare metal devices.”
There is a higher concentration of high obesity populations in poorer areas. Economists point to the relatively lesser price of high calorie high fat foods, and the high cost of diets composed of whole grains, fish, and fresh vegetables and fruit. Results from a national survey on childhood obesity show that over 17 percent of adolescent ages 2-19 years are overweight. Obesity at such a young age accelerates the onset of type II diabetes, due to which the risks of a major cardiovascular event are amplified. The future of advanced cardiovascular care is facing a customer base with heightened demand, but a diminished capacity to pay for high end technologies.
In the coronary stent market, there are the entrenched market leaders, and those knocking on the door hoping to grab a share of this $3.2 billion market. The next several years will see new product launches from other competitors such as Medtronic, Guidant, Abbott Laboratories, and in the long term even possibly niche manufacturers able to take their device to market. Even current market participants; such as, Boston Scientific with its Taxus Liberte and Cordis/ J&J with its Cypher Select are developing second generations of their popular devices.
"The majority of clinicians who are satisfied with the performance of the stents they are currently using, will lack incentive to incorporate a new device into their practice," explains Rajan. "Only a device with a novel approach and significant clinical benefit over existing products will be capable of achieving high levels of initial market growth."
With the surge in patient demand, it is important to perform procedures that are quick, cost effective, and require the least amount of additional hospital attention. PCI procedures are routine. They involve minimal scarring and have quick recovery times. Therefore, they will be the predominant therapy of choice in revascularization in the near and long term market future.
U.S. Coronary Stent Market is part of the Medical Devices Growth Partnership Service, and it provides an overview of the trends and technologies that have shaped market revenues, market share, and implantation rates in the individual segments of the market. In this research, Frost & Sullivan's expert analysts thoroughly examine the drug eluting and bare metal stents markets along with the coronary care trends in the U.S. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.